Skip to main content
Original Research, Transplant, Obesity, Chemotherapy
Impact of Using Adjusted Body Surface Area in Obese Patients Receiving Ablative Busulfan plus Fludarabine Conditioning Regimen Before Hematopoietic Stem-Cell Transplant
Katelyn A. Zink, PharmD, BCOP, Jill Stein, PharmD, BCOP, Patrick Ten Eyck, MS, PhD, Meredith Ginn, PharmD, BCOP
Katelyn A. Zink, PharmD, BCOP; Jill Stein, PharmD, BCOP; Patrick Ten Eyck, MS, PhD; Meredith Ginn, PharmD, BCOP
Read More
Original Research, Antibiotics, Infections
Evaluating Antibiotic Use and Opportunities for Intervention in Patients with Cancer
Corey Medler, PharmD, MPH, Rachel Kenney, PharmD, BCIDP, Susan Davis, PharmD
Corey Medler, PharmD, MPH; Rachel Kenney, PharmD, BCIDP; Susan Davis, PharmD
Read More
Gastrointestinal Cancers
Nivolumab Demonstrates Significant Overall Survival Benefits in Patients with Previously Treated Esophageal Squamous-Cell Carcinoma Compared with Chemotherapy
Read More
Gastrointestinal Cancers
Trifluridine/Tipiracil and Ramucirumab Demonstrate Antitumor Activity in Previously Treated Unresectable Advanced Gastric or Gastroesophageal Cancer
Read More
Gastrointestinal Cancers
Insertion-Deletion Rate Is Associated with Clinical Outcomes in Nivolumab-Treated Gastric Cancer
Read More
Gastrointestinal Cancers
Surufatinib in Combination with Toripalimab Demonstrates Antitumor Responses in Previously Treated Patients with Gastric or Gastroesophageal Adenocarcinoma
Read More
Gastrointestinal Cancers
Analysis of PD-L1 Expression by Combined Positive Score May Help Identify Which Patients with Advanced Gastric/Gastroesophageal Junction Cancer Will Respond to Treatment with Nivolumab and Ipilimumab
Read More
Gastrointestinal Cancers
Ramucirumab plus Paclitaxel Confers an Overall Survival Advantage Over Placebo in the RAINBOW-Asia Study
Read More
Gastrointestinal Cancers
Zolbetuximab in Combination with Epirubicin/Oxaliplatin/Capecitabine Shows Survival Advantage in Patients with Gastric, Gastroesophageal Junction, and Esophageal Cancer: The FAST Study
Read More
Gastrointestinal Cancers
Second-Line Nivolumab with Paclitaxel plus Ramucirumab Shows Promising Antitumor Responses in Patients with Advanced Gastric Cancer
Read More
Page 80 of 200
Results 791 - 800 of 1993